ESMO 2012: Duration of trastuzumab in HER2-positive early breast cancer: what is the standard?

ESMO has 24 videos Subscribe Here

Description: Sandra Swain compares results of the PHARE and the HERA trials about the optimal duration of trastuzumab for HER2-positive early breast cancer and draws important conclusions for patients. These studies were presented during ESMO 2012, the Congress of the European Society for Medical Oncology. Read all the news about the latest in cancer and oncology from the Congress here

The opinion expressed in this interview reflects that of the interviewee and does not necessarily express the official ESMO point of view.
Video produced by the European Society for Medical Oncology (ESMO)
Access all the ESMO scientific video resources:
Shared By : ESMO
Posted on : 10/29/12
Added : 5 years ago
Category : News

More From ESMO

Nothing found.